BIOCLEAN FIRST CARE EX in Combination With Biofinity Lens

NCT ID: NCT02196766

Last Updated: 2020-07-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine if patients are unreactive to the lens care solution / Biofinity combination.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To determine if patients are unreactive to the lens care solution / Biofinity combination in this cross-over study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bioclean First Care EX combo, then Aosept Clearcare combo

Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the Aosept Clearcare / comfilcon A combination.

Group Type ACTIVE_COMPARATOR

Bioclean First Care EX / comfilcon A

Intervention Type OTHER

Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.

Aosept Clearcare / comfilcon A

Intervention Type OTHER

Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.

Aosept Clearcare combo, then Bioclean First Care EX combo

Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the Bioclean First Care EX / comfilcon A combination.

Group Type ACTIVE_COMPARATOR

Bioclean First Care EX / comfilcon A

Intervention Type OTHER

Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.

Aosept Clearcare / comfilcon A

Intervention Type OTHER

Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bioclean First Care EX / comfilcon A

Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.

Intervention Type OTHER

Aosept Clearcare / comfilcon A

Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is over 18 years of age (inclusive)
* Has had a self-reported visual exam in the last two years
* Is currently an adapted spherical soft CL wearer
* Has a CL spherical prescription between - 0.25 and - 12.00 (inclusive)
* Has less than 1.00D spectacle cylinder in each eye.
* Is correctable to a visual acuity of 20/20 or better in both eyes
* Has clear corneas and no active ocular disease
* Has read, understood and signed the information consent letter.
* Is willing to comply with the wear schedule (at least 40 hrs per week)
* Is willing to comply with the visit schedule

Exclusion Criteria

* Has never worn contact lenses before.
* Currently wears rigid gas permeable contact lenses.
* Has a history of not achieving comfortable CL wear (5 days per week; \> 8 hours/day)
* Has a CL prescription outside the range of - 0.25 to -12.00D
* Has a spectacle cylinder greater than -0.75D of cylinder in either eye.
* Has best corrected spectacle distance vision worse than 20/20 in either eye.
* Has any systemic disease affecting ocular health.
* Is using any systemic or topical medications that will affect ocular health.
* Has any ocular pathology or severe insufficiency of lacrimal secretion
* Has persistent, clinically significant corneal or conjunctival staining
* Has active neovascularization or any central corneal scars.
* Is aphakic.
* Is pregnant or lactating.
* Has undergone corneal refractive surgery.
* Is participating in any other type of eye related clinical or research study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CooperVision, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Taku Muraoka, OD

Role: STUDY_DIRECTOR

Director Professional Services, CVI Japan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kokama Eye Clinic

Joyo-shi, Kyoto, Japan

Site Status

Higashihara Clinic

Kameoka, Kyoto, Japan

Site Status

Dougenzaka Ioti Eye Clinic

Shibuya-ku, Tokyo-to, Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CVJ-EX-MKTG-1818

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.